InvestSMART

Acumentis Group Limited (ASX: ACU) - Announcements

- Current share price for ACU : $0.083

ASX company news and announcements for Acumentis Group Limited (ACU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acumentis Group Limited (ACU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acumentis Group Limited (ACU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acumentis Group Limited (ACU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 ACU`s Hawaii Biotech Enters Clinic with West Nile Vaccine 24 Jun 2008 10:03AM n/a $0.083 n/a
$19 Avantogen and Medingen Complete Encore Line of Supplements 7 May 2008 11:29AM $0.060 $0.083 risen by 38.33%
$19 Commitments Test Entity - Third Quarter Report 30 Apr 2008 2:23PM $0.060 $0.083 risen by 38.33%
$19 ACU Vaccine Development Affiliate Wins Major Funding Support 9 Apr 2008 1:40PM $0.047 $0.083 risen by 76.60%
$19 Avantogen Re-Acquires Pentrys Cancer Vaccine 17 Mar 2008 3:43PM $0.025 $0.083 risen by 232%
$19 Half Yearly Report and Accounts 29 Feb 2008 1:10PM n/a $0.083 n/a
$19 Avantogen Ltd Completes $1M Placement 12 Feb 2008 2:06PM $0.033 $0.083 risen by 151.52%
$19 Response to ASX Query re Appendix 4C 6 Feb 2008 9:46AM $0.033 $0.083 risen by 151.52%
$19 Pancreatic Cancer Drug Progress by USA Partner 5 Feb 2008 5:17PM n/a $0.083 n/a
$19 Appendix 4C - quarterly 30 Jan 2008 4:10PM $0.033 $0.083 risen by 151.52%
$19 Avantogen Affiliate Hawaii Biotechnology Achieves Milestone 8 Jan 2008 8:28AM $0.065 $0.083 risen by 27.69%
$19 Letter of Intent for $8M Equity Injection at 7 Cents 3 Dec 2007 6:29PM $0.060 $0.083 risen by 38.33%
$19 Appendix 4C - quarterly 30 Oct 2007 8:28AM $0.043 $0.083 risen by 93.02%
$19 RP101 Pancreatic Cancer Drug Advances in Licensing 25 Oct 2007 2:07PM $0.049 $0.083 risen by 69.39%
$19 Reinstatement to official quotation: 3/10/07 2 Oct 2007 3:37PM $0.051 $0.083 risen by 62.75%
$19 Commitments Test Entity - Fourth Quarter Report 31 Jul 2007 5:11PM $0.051 $0.083 risen by 62.75%
$19 Suspension from Official Quotation 11 Sep 2006 10:06AM n/a $0.083 n/a
$19 Trading Halt 7 Sep 2006 11:19AM $0.051 $0.083 risen by 62.75%
$19 Preliminary Results of Study 18 Aug 2006 12:14PM $0.059 $0.083 risen by 40.68%
$19 Board Changes 18 Aug 2006 10:06AM $0.059 $0.083 risen by 40.68%
$19 Trading Halt 16 Aug 2006 9:57AM n/a $0.083 n/a
$19 Response to ASX Appendix 4C Query 14 Aug 2006 9:56AM $0.055 $0.083 risen by 50.91%
$19 Commitments Test Entity - Fourth Quarter Report 1 Aug 2006 8:27AM n/a $0.083 n/a
$19 Progress in the evaluation of RP101 8 Jun 2006 5:31PM $0.064 $0.083 risen by 29.69%
$19 Response to ASX Query 7 Jun 2006 10:05AM $0.080 $0.083 risen by 3.75%

526 - 550 of 601 results

Page 22 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.